Bal Pharma Ltd. — Investor Relations & Filings
Bal Pharma Ltd. specializes in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations. The organization operates manufacturing facilities compliant with international quality standards, including WHO-GMP certifications. Its product portfolio encompasses a wide range of therapeutic segments, including diabetology, cardiology, gastroenterology, oncology, and pain management. Notable APIs in its catalog include Gliclazide, Ebastine, and Benzydamine. The company maintains an integrated business model, supporting operations from research and development to large-scale production. Bal Pharma serves a global clientele, exporting its products to numerous international markets across multiple continents, while focusing on the delivery of high-quality medicinal products and specialized formulations.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Financial Result Updates | 2024-05-28 | English | |
| Outcome of Board Meeting | 2024-05-28 | English | |
| Loss of Share Certificates | 2024-05-21 | English | |
| Disclosure under SEBI Takeover Regulations | 2024-04-23 | English | |
| Statement of deviation(s) or variation(s) under Reg. 32 | 2024-04-18 | English | |
| Loss of Share Certificates | 2024-04-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
12 filings
| |||||
| 42657730 | Financial Result Updates | 2024-05-28 | English | ||
| 42657898 | Outcome of Board Meeting | 2024-05-28 | English | ||
| 42629351 | Loss of Share Certificates | 2024-05-21 | English | ||
| 42627473 | Disclosure under SEBI Takeover Regulations | 2024-04-23 | English | ||
| 42601915 | Statement of deviation(s) or variation(s) under Reg. 32 | 2024-04-18 | English | ||
| 42612919 | Loss of Share Certificates | 2024-04-17 | English | ||
| 42647521 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2024-04-05 | English | ||
| 42652665 | Trading Window | 2024-03-22 | English | ||
| 42686919 | Copy of Newspaper Publication | 2024-02-14 | English | ||
| 42725996 | Outcome of Board Meeting | 2024-02-12 | English | ||
| 42726038 | Financial Result Updates | 2024-02-12 | English | ||
| 42681400 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2024-01-02 | English | ||
|
2023
3 filings
| |||||
| 42676228 | Trading Window | 2023-12-28 | English | ||
| 42709117 | Shareholders meeting | 2023-12-22 | English | ||
| 42683897 | Shareholders meeting | 2023-12-21 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bal Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/59392/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=59392 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=59392 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=59392 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 59392}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bal Pharma Ltd. (id: 59392)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.